Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zhong WY, Fogelman D, Marinello P, Andre T; KEYNOTE-177 Investigators. Diaz LA Jr, et al. Lancet Oncol. 2022 May;23(5):659-670. doi: 10.1016/S1470-2045(22)00197-8. Epub 2022 Apr 12. Lancet Oncol. 2022. PMID: 35427471 Free PMC article. Clinical Trial.
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J, Colomer R, Cortés-Funes H, Jimeno A. Grávalos C, et al. Clin Transl Oncol. 2011 Mar;13(3):179-84. doi: 10.1007/s12094-011-0637-6. Clin Transl Oncol. 2011. PMID: 21421462 Clinical Trial.
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.
Gravalos C, Salut A, García-Girón C, García-Carbonero R, León AI, Sevilla I, Maurel J, Esteban B, García-Rico E, Murias A, Cortés-Funes H. Gravalos C, et al. Clin Transl Oncol. 2012 Aug;14(8):606-12. doi: 10.1007/s12094-012-0843-x. Epub 2012 Jul 19. Clin Transl Oncol. 2012. PMID: 22855138 Free PMC article. Clinical Trial.
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S, Burdaeva O, Rivera F, Samuel L, Bulavina I, Potter V, Chang YL, Lokker NA, O'Dwyer PJ. Tabernero J, et al. Clin Cancer Res. 2013 May 1;19(9):2541-50. doi: 10.1158/1078-0432.CCR-13-0107. Epub 2013 Mar 26. Clin Cancer Res. 2013. PMID: 23532888 Clinical Trial.
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
Garcia-Carbonero R, Rivera F, Maurel J, Ayoub JP, Moore MJ, Cervantes A, Asmis TR, Schwartz JD, Nasroulah F, Ballal S, Tabernero J. Garcia-Carbonero R, et al. Oncologist. 2014 Apr;19(4):350-1. doi: 10.1634/theoncologist.2014-0028. Epub 2014 Mar 27. Oncologist. 2014. PMID: 24674871 Free PMC article. Clinical Trial.
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.
Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor MD, Chaves M, Suarez R, Paz-Ares L, de la Portilla F, Carranza-Carranza A, Sevilla I, Vicioso L, Garcia-Carbonero R. Molina-Pinelo S, et al. BMC Cancer. 2014 Sep 7;14:656. doi: 10.1186/1471-2407-14-656. BMC Cancer. 2014. PMID: 25197016 Free PMC article.
220 results